Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. Highlighted discussion of implantable stimulators, urine proteomics and gut-immune responses to Prevotella in RA.

Few drugs have been studied well in the treatment of dermatomyositis (DM) and only recently has intravenous immune globulin (IVIG) been granted FDA approval for the treatment of DM, based on this pivotal trial.

Dr. Jack Cush goes off on "Untitling" (not using proper names/titles) in the clinic, in addition to reports on rheumatologist salaries, new drugs in phase 1-3 development and the range of COVID-19 MSK symptoms -- all from the past week on RheumNow.com.

Juvenile idiopathic arthritis (JIA) may start in adolescence and extend into adulthood.

While it is known that smoking ups the risk of developing RA, its effect on outcomes in those with established rheumatoid arthritis (RA) is less known.  A report from an early arthritis registry shows that current smoking increases disease activity and lowers health-related quality of life.

This week it's the great and not-so-great on gout, chondrocalcinosis, osteoporosis and misdiagnosis. We are good at many of those things - what's not so great? Let's review the news and journal reports from the past week on RheumNow.

The Lasker Foundation has announced the winners of its 2022 Lasker Awards, widely regarded as America’s top biomedical research prize since its creation more than 75 years ago. Here's a look at the award winners and their important contributions to biomedical research.

Using long-term patient data from the BARFOT study of early rheumatoid arthritis (RA) patients, researchers at the Karolinska Institute have shown that use of the ACR-1987 classification criteria was highly precise.

Below are this week’s highlights from RheumNow, as discussed by Dr. Jack Cush. Thanks to all of you for your kind comments and great reviews of our weekly podcast. Please let us know how we can improve by emailing me or recording your suggestion using the "Ask Cush Anything" link on our website.

A recent review of the myositis associated autoantibody NXP-2 profiles its clinical associations with dermatomyositis (DM), calcinosis, severe myositis and, in some reports, with cancer.

A systematic review suggests that low-dose methotrexate (MTX) use is associated with an increased melanoma risk, but the absolute risk increase could be considered negligible.

Two large RA registries have shown that pregnancy outcomes in rheumatoid arthritis (RA) patients is more related to RA disease activity rather than treatments use to control RA. 

Can we predict the bad outcomes? Like when ITP evolves into SLE; or when psoriasis will develop arthritis; or if Sjogren's will develop lymphoma? Let's dive in and review these journal reports and this past week's news from RheumNow.com.

Rheumatoid arthritis patients with existing interstitial lung disease (ILD) had less decline in lung function when receiving the antifibrotic agent pirfenidone (Esbriet) relative to placebo in a randomized trial, researchers reported here and in a simultaneous journal publication.

An integrated analysis of two pivotal trials of voclosporin, a calcineurin inhibitor, in lupus nephritis patients saw significant improvement in complete renal responses (CRR) at one year.

Dr. Jack Cush discusses declining survival rates in the USA, FDA approvals of new COVID subvariant boosters and other odd and possibly true new research reports from the past week on RheumNow.com.

Not all patients with periodic fevers fit neatly into diagnostic categories. Some can be diagnosed as Still’s disease (based on criteria) while others can be classified as autoinflammatory diseases (AID) and some may be unclassifiable, clinically or genetically.

The diagnosis of idiopathic inflammatory myopathies (IIMs) can be informed by the 2017 EULAR/ACR classification criteria, but their utility in patients with clinically amyopathic dermatomyositis (CADM) and anti–melanoma differentiation–associated protein 5 (anti–MDA-5)–positive IIM

NICE (UK) has systematically reviewed current medical evidence and delivered a set of recommendations with consideration of cost effectiveness.